Free Trial
OTCMKTS:CRNCV

Cerence (CRNCV) Stock Price, News & Analysis

Cerence logo
$9.51 +0.21 (+2.26%)
As of 05/16/2025

About Cerence Stock (OTCMKTS:CRNCV)

Key Stats

Today's Range
$9.33
$9.58
50-Day Range
$6.88
$10.32
52-Week Range
$17.25
$29.36
Volume
554,366 shs
Average Volume
75,989 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CRNCV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerence and its competitors with MarketBeat's FREE daily newsletter.

CRNCV Stock News Headlines

Q1 2025 Cerence Inc Earnings Call
Cerence Shares Surge After Beating 4Q Estimates
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
CytoDyn announces FDA clearance of Phase II oncology trial
Cerence Inc. (CRNC)
See More Headlines

CRNCV Stock Analysis - Frequently Asked Questions

Cerence's stock was trading at $7.85 at the beginning of the year. Since then, CRNCV shares have increased by 21.1% and is now trading at $9.51.
View the best growth stocks for 2025 here
.

Shares of CRNCV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Packaged Software
Sub-Industry
N/A
Current Symbol
OTCMKTS:CRNCV
CIK
N/A
Phone
N/A
Fax
N/A
Employees
1,300
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (OTCMKTS:CRNCV) was last updated on 5/20/2025 by MarketBeat.com Staff
From Our Partners